» Articles » PMID: 10688870

Tumor Progression and Metastasis

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2000 Feb 26
PMID 10688870
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

It is now widely accepted that cancer is attributed to the accumulation of genetic alterations in cells. Thus, to understand the molecular mechanisms of cancer metastasis, it is indispensable to identify the genes whose alterations accumulate during cancer progression as well as the genes whose expression is responsible for the acquisition of metastatic potential in cancer cells. Molecular analyses of cancer cells in various stages of progression have revealed that alterations in tumor suppressor genes and oncogenes accumulate during tumor progression and correlate with the clinical aggressiveness of cancer. Comparative analyses of gene expression profiles between metastatic and non-metastatic cells have revealed that various genes are differentially expressed in association with the metastatic potential of cancer cells. A number of genes have been also identified as having functions in inducing or suppressing metastasis in experimental models. However, the association between causative genetic alterations and resulting phenotypic alterations with respect to the metastatic potential of cancer cells is not fully understood. Therefore, elucidation of genotype-phenotype correlation will be required to further understand a complex process of metastasis. Here, I review the progress on molecular studies of tumor progression and metastasis of the past 20 years and discuss the future direction in this field of science.

Citing Articles

A Review of Talin- and Integrin-Dependent Molecular Mechanisms in Cancer Invasion and Metastasis.

Baster Z, Russell L, Rajfur Z Int J Mol Sci. 2025; 26(5).

PMID: 40076426 PMC: 11899650. DOI: 10.3390/ijms26051798.


Explainable Machine Learning Models Using Robust Cancer Biomarkers Identification from Paired Differential Gene Expression.

Diaz de la Guardia-Bolivar E, Martinez Manjon J, Perez-Filgueiras D, Zwir I, Del Val C Int J Mol Sci. 2024; 25(22).

PMID: 39596491 PMC: 11594711. DOI: 10.3390/ijms252212419.


Exploring Tumor Heterogeneity: Radiogenomic Assessment of ADFP in Low WHO/ISUP Grade Clear Cell Renal Cell Carcinoma.

Greco F, Panunzio A, DAndrea V, Vescovo M, Tafuri A, Carotti S Cancers (Basel). 2024; 16(18).

PMID: 39335136 PMC: 11430299. DOI: 10.3390/cancers16183164.


Detection of the Fatty Acid Metabolism-Linked Genes in Lung Adenocarcinoma as Biomarkers for Clinical Prognosis and Immunotherapeutic Targets.

Shi J, Yang R, Jiang X, Zhu K, Liu Z Clin Respir J. 2024; 18(10):e70013.

PMID: 39323079 PMC: 11424681. DOI: 10.1111/crj.70013.


Understanding the Landscape of Multi-Cancer Detection Tests: The Current Data and Clinical Considerations.

Cotner C, ODonnell E Life (Basel). 2024; 14(7).

PMID: 39063649 PMC: 11278188. DOI: 10.3390/life14070896.